Around the Practice

A panel of experts discuss recent data results and updates happening within the HER2+ breast cancer treatment landscape.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

A panel of experts review data from recent conferences and discuss core challenges in the treatment of patients with HER2+ metastatic breast cancer.

A panel of experts discusses current strategies used to stratify risk in patients with myelofibrosis and their preferences for sequencing therapy.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

Shared insight on strategies for optimizing frontline therapy for patients with newly diagnosed multiple myeloma, including those with high-risk disease.

A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.

Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.

Experts in bladder cancer discuss best practices for treating patients with locally advanced and metastatic urothelial carcinoma.

Experts discuss best practices for treating patients with metastatic HER2+ breast cancer and consider optimal treatment options for patients with brain metastases and visceral disease.

Experts discuss best practices for treating patients with HER2+ breast cancer and suspected or actual brain metastases, as well as considerations for treatment sequencing and the identification and management of interstitial lung disease.

Experts in urology and nuclear medicine discuss the identification and management of biochemical recurrence in prostate cancer using 2 patient cases as examples.

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.